Once the order ıs locked, three delivery modes carry the work.
Launch Studio, Market Accelerator, and Adoption Strategy are how Cenvia delivers — not three separate offerings to choose between. Each market on your sequence activates the right combination, in the right order.
You don't choose between them. The sequence does.
The Sequencing Assessment tells you which markets to enter and in what order. This is what happens next. We lead the regulatory, reimbursement, pricing, and evidence work that gets each market launch-ready — and design the post-launch strategy that turns approval into uptake. The commercial motion stays with your team. We make sure they're set up to win it.
Most launches activate all three delivery modes — but rarely all three at the same time, and never in the same configuration twice.
The first one or two markets on your sequence trigger Launch Studio. Subsequent markets trigger Market Accelerator. Once a market has approval and reimbursement, Adoption Strategy takes over for the post-launch motions. Across a full launch programme, the three modes overlap, hand off, and re-engage as new markets come online.
The point of running it this way is continuity. The principal who led your first market is the same principal coordinating the third. The dossier built for Germany is the foundation for the submission to Japan. The KOL relationships established during Launch Studio feed into Adoption Strategy. Nothing starts from scratch in a second market that didn't have to.
A quarterly sequence review keeps the order honest as markets evolve, competitive moves land, and your own evidence base grows. The sequence is locked at the end of the Assessment, but it isn't frozen.
Launch Studio.
Set up the first launch.
The Studio leads the regulatory, market access, pricing, and evidence work in the first market — or sometimes the first two — in your sequence. A small team of principals owns outcomes. Modality-specific consultants plug in for the specialist work — cell therapy CMC, AI/SaMD pathways, rare disease HTA — and exit when their part is done.
This is where the foundation gets laid. Decisions made here become the comparator, the pricing precedent, and the evidence base for every market that follows. Choose to compress the timeline here at your peril; the cost of a poor first-market decision compounds across the rest of your portfolio.
Best when
You're launching a first-in-class asset where regulatory and access decisions are entangled — and the first market needs to be right rather than fast.
What's inside
- Regulatory strategy & filing leadership
- Market access plan and HTA submission
- Pricing & contracting framework
- Evidence plan, including real-world evidence design
- Cross-functional launch governance
Market Accelerator.
Open the next markets faster.
Once the first market is live, the Accelerator extends the regulatory and access work into subsequent geographies on your sequence. We reuse dossiers, evidence, pricing precedent, and stakeholder relationships built upstream — compressing the time and cost to open each additional market.
The work itself is more familiar this time. The regulatory strategy isn't being invented; it's being adapted. The pricing rationale isn't being constructed; it's being defended against a new reference market. The evidence isn't being designed; it's being repurposed. That's what makes the Accelerator faster and cheaper than running each market as a standalone Launch Studio — and why doing it without the Studio behind it usually doesn't work.
Best when
A first launch has succeeded and you need disciplined geographic expansion without rebuilding the access workstream in each market.
What's inside
- Country-specific regulatory adaptation
- Local HTA and reimbursement submissions
- Pricing reference management across markets
- Distributor and partner selection advisory
- Cross-market evidence reuse
- Local access team scoping
Adoption Strategy.
Design the path from approval to use.
Approval is a milestone, not an outcome. Adoption Strategy designs the post-launch motions that drive uptake — the KOL strategy, the evidence plan, the patient pathway work that sets your commercial team up to turn approval into real-world use.
Note the word designs. We design the strategy. Your commercial team — your MSLs, your sales force, your medical affairs, your access team — executes it. This is a deliberate boundary. The teams who run adoption day-to-day need to own it. Our job is to design a strategy worth owning, hand it off cleanly, and stay available when the metrics need course-correction.
Best when
Reimbursement is secured but uptake is not — or when adoption strategy needs to be tailored market by market because what worked in one geography doesn't transfer.
What's inside
- KOL and advisory board strategy
- Real-world evidence design and oversight
- Patient pathway and access strategy
- Medical affairs strategy
- Payer evidence dossier design
- Adoption metrics framework
Principals own outcomes. Modality consultants supply depth.
Every engagement is led by a principal — a senior operator who has run launches end-to-end inside biopharma or medtech companies. The principal sits in the room with your CEO and board, owns the sequencing call, and stays accountable from kick-off through adoption.
Modality consultants are activated underneath the principal when the work demands their depth. A cell and gene therapy launch needs CMC depth that a generalist principal can't supply alone. A rare disease HTA submission needs someone who has lived in the relevant reimbursement pathway. An AI/SaMD device needs regulatory specialists who understand evolving guidance on software-as-medical-device.
These consultants are vetted by the principals before activation, embedded under principal oversight while active, and retired when their part of the work is done. You pay for depth when you need it, not as a permanent overhead.
The model is modular by design. It also means there is one named human accountable to you across every market and every milestone — not a rotating cast of associates.
Per market. Retainer or project.
Unlike the Sequencing Assessment, execution work isn't a fixed-fee engagement. The scope varies too much across modalities, markets, and asset complexity to price it that way honestly.
What we do commit to is structure. Each market on your sequence is scoped separately, with a defined principal, a defined consultant team, a defined deliverable set, and a defined retainer or project fee. You see exactly what you're paying for each market, and you can pause, expand, or redirect between markets as the sequence evolves.
A quarterly sequence review is built into every execution engagement. It keeps the order honest as markets, evidence, and competitive conditions change.
We will not run an execution engagement without a Sequencing Assessment behind it.
Start wıth the sequence.
Execution without sequencing is what stalled launches look like. If you haven't done a Sequencing Assessment, that's the right starting point. If you have, and you're ready to activate the first markets, talk to us.